Found 534 hits.
| 69 | Magerl, M., Schmolke, J., Metz, M., Zuberbier, T., Siebenhaar, F., and Maurer, M.+: Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clin. Exp. Dermatol. 2009: 34; e137-e140. IF: 1.55 |
| 363 | Schoepke, N., Asero, R.*, Ellrich, A.*, Ferrer, M.*, Giménez-Arnau, A.*, Gratten, C. E. H.*, Jakob, T.*, Konstantinou, G. N.*, Raap, U.*, Stahl Skov, P.*, Staubach, P.*, Kromminga, A.*, Zhang, K.*, Bindslev-Jensen, C., Daschner, A., Kinaciyan, T., Knol, E. F., Makris, M., Marrouche, N., Schmid-Grendelmeier, P., Sussman, G., Toubi, E., Church, M. K., and Maurer, M.+: Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST study. Allergy 2019: 74; 2427-2436. IF: 8.71 |
o.363
| 27. | Młynek, A., Maurer, M., and Zalewska, A.: Update on chronic urticaria: focusing on mechanisms. Curr. Opin. Allergy Clin. Immunol. 2008: 8; 433-437. IF: 3.50 |
| 249 | Kessel, A.+, Graif, Y., Vadasz, Z., Schichter-Konfino, V., Almog, M., Cohen, S., Teplitski, V., Stein, N., Baiardini, I. Maurer, M. and Toubi, E.: Adaption and validation of the Israeli version of the chronic urticaria quality of life questionnaire (CU-Q2oL). IMAJ 2016: 18; 461-465. IF: 1.03 |
| 227 | Hawro, T., Bogucki, A., Krupińska-Kun, M., Maurer, M.+, and Woźniacka, A.: Serum neuron specific enolase – a novel indicator for neuropsychiatric systemic lupus erythematosus? Lupus 2015: 24; 1492-1497. IF: 2.11 |
o.227
| 177 | Ale, A., Siebenhaar, F., Kosanke, K., Aichler, M., Radrich, K., Heydrich, S., Schiemann, M., Bielicki, I., Noel, P. B., Braren, R., Maurer, M. Walch, A. K., Rummeny, E. J., Nztiachristos, V., and Wildgruber, M.+: Cardioprotective C-kit+ bone marrow cells attenuate apoptosis after acute myocardial infarction in mice – in vivo assessment with fluorescence molecular imaging. Theranostics 2013: 3; 903-913. IF: 7.83 |
o.177
| 384. | Sabag, D. A.*, Matanes, L.*, Bejar, J., Sheffer, H., Barzilai, A., Church, M. K., Toubi, E., Maurer, M., and Vadasz, Z.+: Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin. Exp. Allergy 2020: 50; 799-804. IF: 5.02 |
o.384
|
495. |
Brzoza, Z.+, Badura-Brzoza, K., Maurer, M., Hawro, T., and Weller, K.: Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria – results from the validation of the Polish urticaria control test. World Allergy Organ J. 2022: 15; 100635. IF: 5.10 |
o.495
| 336 | Kocatürk, E.+, Kiziltac, U., Can, P., Öztas Kara, R., Erdem, T., Kiziltac, K., Sahillioglu, N., Gelincik, A., Maurer, M., and Weller, K.: Validation of the Turkish version of the urticaria control test: correlation with other tools and comparison between spontaneous and inducible chronic urticaria. World Allergy Organ. J. 2019: 12; 6-13. IF: TBD (IF 2018: 3.68) |
o.336
| 124. | Sánchez-Borges, M., Caballero-Fonseca, F., Capriles-Hulett, A., González-Aveledo, L., and Maurer, M.: Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria. J. Eur. Acad. Dermatol. Venereol. 2017: 31; 964-971. IF: 4.29 |
r.124